Checkpoint Therapeutics, Inc. (CKPT)
4.260
0.00 (0.00%)
Inactive · Last trade price on May 29, 2025
Checkpoint Therapeutics Employees
Checkpoint Therapeutics had 24 employees as of December 31, 2024. The number of employees increased by 1 or 4.35% compared to the previous year.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$1,708
Profits / Employee
-$2,354,458
Market Cap
356.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 1 | 4.35% |
| Dec 31, 2023 | 23 | -1 | -4.17% |
| Dec 31, 2022 | 24 | 10 | 71.43% |
| Dec 31, 2021 | 14 | 4 | 40.00% |
| Dec 31, 2020 | 10 | 2 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
CKPT News
- 4 months ago - Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewsWire
- 4 months ago - CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT - Business Wire
- 5 months ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 6 months ago - Sun Pharma to Acquire Checkpoint Therapeutics - PRNewsWire
- 9 months ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 9 months ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 10 months ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 10 months ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire